OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
OCULAR THERAPEUTIX, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$6.29−0.58 (-8.44%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.55 (−46.88%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
OCULAR THERAPEUTIX, INC saw revenue fall 8.1% to $52.05M over the twelve months to Jun 30, 2026. Free cash flow was -$255.10M.
Revenue
$52.05M
-8.1% vs. a year earlier
Operating income
-$313.91M
TTM Q2 2026
Free cash flow
-$255.10M
TTM Q2 2026
EPS, diluted
-$1.42
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.41B
- P/E ratio
- –
- Price to sales
- 27.18
- Price to book
- 2.72
- Dividend yield
- –
- Free cash flow yield
- -18.03%
Fundamentals
- Revenue
- $52.05M
- Net income
- -$301.45M
- EPS, diluted
- -$1.42
- Free cash flow
- -$255.10M
- Book value per share
- $2.31
- Diluted shares
- 225M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$52.05M-8.1% YoY
Gross profit
$45.35M-10.5% YoY
Operating income
-$313.91M
Net income
-$301.45M
EPS, diluted
-$1.42
Free cash flow
-$255.10M
Reported periodTrailing twelve months